According to a recently published report by Roots Analysis, the success of 14 approved antibody drug conjugates (ADCs) and a promising developmental pipeline is driving the antibody drug conjugate market growth.

Roots Analysis, in its latest report, titled, “Antibody Drug Conjugate Market (7th Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions (North America, Europe, and Asia-Pacific),” observes that the market stood at USD 7.72 billion in 2023 and is projected to reach USD 23 billion by 2035.

For more information visit here https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/270.html

Out research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.

What does the Antibody Drug Conjugate Market Report Include?

The Antibody Drug Conjugate market report includes quantitative and qualitative analysis of several factors such as the key drivers and restraints that will impact growth. Additionally, the report provides insights into the regional analysis that covers different regions, which are contributing to the growth of the market. It includes the competitive landscape that involves the leading companies and the adoption of strategies by them to introduce new products, announce partnerships, and collaborations that will contribute to the growth of the market between 2023 and 2035.

Moreover, the research analyst has adopted several research methodologies such as Antibody Drug Conjugate service providers: current market landscape, company competitiveness analysis, technology competitiveness analysis, partnerships and collaborations analysis, funding and investment analysis, licensing deal structure, market forecast and opportunity analysis to extract information about the current trends and industry developments that will drive the market growth in the forthcoming years.

Key Market Insights

Around 250 ADCs are currently under development

Of these, nearly 40% are in the clinical phase of development, while the rest are in the preclinical / discovery stage. Presently, most of such therapeutic leads are being developed against the HER2 antigen; other popular biological targets include CD30 and EGFR.

60% of clinical stage therapy candidates are designed for the treatment of solid tumors

Within this segment, breast cancer (which represents a share of 22%) is currently the most popular target indication (in terms of number of therapy candidates in the pipeline), followed by non-small cell lung cancer (10%). ADC therapeutics are also being developed for hematological malignancies, such as multiple myeloma (31%), lymphoma (27%) and leukemia (27%).

More than 11,000 patents have been filed / granted related to ADCs and affiliated technologies, since 2015

Around 40% of these intellectual property documents were filed / granted in the US; other key regions with significant intellectual capital include China, Japan, Canada, Korea and Taiwan. Leading non industry players (in terms of the size of intellectual property portfolio) include INSERM, University of California, Leland Stanford Junior University and University of Pennsylvania.

USD 5+ billion has been invested by both private and public investors, till 2019

Around USD 2 billion was raised through venture capital financing alone, representing 40% of the total capital amount raised since 2011. Further, there have been six IPOs, from which companies claim to have raised over USD 1 billion in financing.

An Overview of the Impact of COVID-19 on this Antibody Drug Conjugate Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of corona virus outbreak across industries to help you prepare for the future. Industry developments that will drive the market growth in the forthcoming years.

Major Antibody Drug Conjugate Market Key players covered in the report include:

ADC Therapeutics, Astellas Pharma, AstraZeneca, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, Pfizer, RemeGen.

Geographically, the main regions covered by the Antibody Drug Conjugate Market report are:

• North America – United States, Canada
• Asia-Pacific – China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia
• Europe – Germany, France, Italy
• Latin America – Mexico, Brazil, Argentina
• Middle East and Africa – Turkey, Saudi Arabia, United Arab Emirates

The market has been analyzed across the following segments:

Type of Payload
MMAE
DM4
Camptothecin
DM1
MMAF
Others
Type of Linker
VC
Sulfo-SPDB
SMCC
VA
Hydrazone
Others
Target Indication
Breast cancer
Lymphoma
Leukemia
Urothelial cancer
Lung cancer
Ovarian cancer
Others
Target Antigen
CD30
HER2
CD22
CD33
Others
Technology Providers
Seattle Genetics
ImmunoGen
StemCentRx
Immunomedics
Others
Key Geographical Regions
North America
Europe
Asia Pacific

Read more @ https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/270.html

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture catalysts and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
All our analysts are trained to produce high quality research work. They are continuously mentored by senior experts to present an original, unbiased and informed perspective on pressing issues in the industry. On any particular subject, we bring together the best available resources to ensure highest quality in all our reports.

Contact Details
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]
Website: https://www.rootsanalysis.com/